Background and Purpose—In the SOCRATES trial (Acute Stroke or Transient Ischemic
Attack Treated With Aspirin or Ticagrelor and Patient Outcomes), ticagrelor was not superior …

Background Ticagrelor may be a more effective antiplatelet therapy than aspirin for the
prevention of recurrent stroke and cardiovascular events in patients with acute cerebral …

Importance Prior trials of dual antiplatelet therapy excluded patients with moderate ischemic
stroke. These patients were included in the Acute Stroke or Transient Ischaemic Attack …

Background and Objectives The goal of this work was to investigate the short-term time-
course benefit and risk of ticagrelor with aspirin in acute mild-moderate ischemic stroke or …

Background: Patients with minor acute ischemic stroke or transient ischemic attack are at
high risk for subsequent stroke, and more potent antiplatelet therapy in the acute setting is …

Background Trials have evaluated the use of clopidogrel and aspirin to prevent stroke after
an ischemic stroke or transient ischemic attack (TIA). In a previous trial, ticagrelor was not …

Background and Purpose—SOCRATES (Acute Stroke or Transient Ischemic Attack Treated
With Aspirin or Ticagrelor and Patient Outcomes), comparing ticagrelor with aspirin in …

Background Ticagrelor is an effective antiplatelet therapy for patients with coronary
atherosclerotic disease and might be more effective than aspirin in preventing recurrent …

Background and Purpose: In patients with acute mild-moderate ischemic stroke or high-risk
transient ischemic attack, the THALES trial (Acute Stroke or Transient Ischemic Attack …

1478 Stroke May 2013 significant increase in prespecified bleeding events. In fact, despite
the more potent antithrombotic effect, the risk of intracranial hemorrhage or fatal stroke was …